Multi-Cancer Blood Test Could Significantly Reduce Late-Stage Diagnoses
A simulation model shows that annual liquid biopsy screening would increase early-stage cancer detection by up to 30% while cutting stage IV diagnoses by 45%.
A simulation model shows that annual liquid biopsy screening would increase early-stage cancer detection by up to 30% while cutting stage IV diagnoses by 45%.
The quantitative measurement test is designed to aid in myocardial infarction diagnosis using human plasma samples.
UCLA Health researchers find cell-free DNA combined with machine learning can distinguish ALS from other neurological conditions.
The mass spectrometry-based assay achieved 100% sensitivity in detecting patients who later progressed to cancer in a blinded cohort study.
Electrochemical biosensor aims to simultaneously detect HIV, Hepatitis B, and Hepatitis C in resource-limited settings using RNA-level identification.
Researchers urge clinicians to integrate lipid management into prenatal care to mitigate elevated obstetric complications and cardiovascular risks.
From rising demand for comprehensive IgE profiles to the emergence of molecular allergen diagnostics, laboratories are central to how clinicians prepare for and manage September’s asthma spike.
Study of more than 13,000 individuals demonstrates improved precision for emergency department triage and patient outcomes.
Two biomarker panels demonstrated 91% sensitivity and specificity in symptomatic patients, potentially reducing the need for PET imaging confirmation.
The automated system uses ion exchange HPLC technology to deliver A1c results while detecting common hemoglobin variants.
The agreement aims to improve early detection and management of chronic kidney disease in underserved populations through integrated diagnostics and digital health solutions.
The Cystic Fibrosis Base assay has received IVDR accreditation, ensuring high standards for detecting cystic fibrosis mutations.
TriVerity system demonstrated high sensitivity and specificity across more than 1,200 patients in pivotal SEPSIS-SHIELD trial.